[{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"9b677f8f-b3e7-4b6d-8718-36c028b32cda","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329325","created_at":"2022-04-24T09:02:32.988Z","updated_at":"2024-07-02T16:35:00.993Z","phase":"Phase 2","brief_title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04329325","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • dexamethasone • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-24"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"ffd2ca60-82dd-404f-a539-82d708a898dd","acronym":"OPTIC","url":"https://clinicaltrials.gov/study/NCT02467270","created_at":"2021-01-18T11:52:32.635Z","updated_at":"2024-07-02T16:35:20.731Z","phase":"Phase 2","brief_title":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","source_id_and_acronym":"NCT02467270 - OPTIC","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 283","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 04/14/2020","primary_completion_date":" 04/14/2020","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-06"},{"id":"377a3cf8-424a-4f4e-85f4-ee44fc24c05c","acronym":"TIPHI","url":"https://clinicaltrials.gov/study/NCT04965649","created_at":"2021-07-16T13:53:26.229Z","updated_at":"2024-07-02T16:35:38.671Z","phase":"","brief_title":"Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.","source_id_and_acronym":"NCT04965649 - TIPHI","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" ABL1 • CD8","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-08-30"},{"id":"8d0c3a0e-31fd-4129-8881-4df591e7fa77","acronym":"","url":"https://clinicaltrials.gov/study/NCT05367700","created_at":"2022-05-10T20:53:40.639Z","updated_at":"2024-07-02T16:35:57.615Z","phase":"Phase 1","brief_title":"A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.","source_id_and_acronym":"NCT05367700","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERN-701"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-01-13"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"fc8ea160-534c-4f07-9146-9bacbd05df98","acronym":"","url":"https://clinicaltrials.gov/study/NCT00707083","created_at":"2021-01-18T02:38:41.941Z","updated_at":"2024-07-02T16:36:49.162Z","phase":"Phase 3","brief_title":"Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00707083","lead_sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","biomarkers":" ABL1","pipe":" | ","alterations":" BCR-ABL1 fusion • MLL rearrangement","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • vincristine • dexamethasone • mercaptopurine • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 2231","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-03-05"},{"id":"10c821d4-57ed-453d-9350-3d76dc49a0b9","acronym":"ENESTKorea","url":"https://clinicaltrials.gov/study/NCT03332511","created_at":"2021-01-18T16:27:22.833Z","updated_at":"2025-02-25T15:53:54.268Z","phase":"Phase 4","brief_title":"Efficacy and Safety of Nilotinib in CML-CP","source_id_and_acronym":"NCT03332511 - ENESTKorea","lead_sponsor":"Seoul National University Hospital","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 05/06/2013","start_date":" 05/06/2013","primary_txt":" Primary completion: 10/24/2016","primary_completion_date":" 10/24/2016","study_txt":" Completion: 10/24/2016","study_completion_date":" 10/24/2016","last_update_posted":"2017-11-06"}]